| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC:KONEF) (FRA: SQ2), an evidence-based mental healthcare company announced that its wholly-owned subsidiary KGK Science Inc. completed an open-label study, where Gefion Canada GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin, according to a press release.
Wellbeing Digital Sciences Inc. focuses on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research.
GT4 Technology uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood.
"Transdermal delivery of topically-applied cannabinoids can be difficult and prior to this study, published research demonstrating successful topical delivery did not exist," reads the company press release.
Published in Advances in Therapy, the Gefion Canada study showed "for the first time" that CBD and THC were successfully transported into the bloodstream following application to the skin.
Gefion GT4 technology may provide lower, more steady-state cannabinoid concentrations that minimize psychoactive effects in participants.
"These findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics," per the press release.
According to the researchers, the administration of CBD and THC in this study turned out to be safe and well tolerated by all participants. ‘None of the volunteers experienced any intoxicating effects.”
Topical cannabis may provide the benefit of extended cannabinoid administration without the concern of intoxication, suggesting that it may be beneficial for certain lifestyles and therapeutic indications, according to the study.
Dr. Erin D. Lewis, scientific director at KGK Science said the study represents “an important step forward in cannabis research. This study opens the door for future double-blind, placebo-controlled trials to further investigate topical cannabis delivery.” However, more research is needed.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
Photo: Courtesy Of FLY:D On Unsplash
Posted In: KONEF
